{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:52:23Z","timestamp":1791244343084,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017542","name":"Beijing Hospital","doi-asserted-by":"publisher","award":["YGLX202526"],"award-info":[{"award-number":["YGLX202526"]}],"id":[{"id":"10.13039\/501100017542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571595"],"award-info":[{"award-number":["82571595"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62171299"],"award-info":[{"award-number":["62171299"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.nmd.2026.107398","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:01:47Z","timestamp":1787328107000},"page":"107398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative efficacy of single-cycle intravenous efgartigimod versus intravenous immunoglobulin in generalized myasthenia gravis patients receiving concomitant immunosuppressive therapy"],"prefix":"10.1016","volume":"67","author":[{"given":"Haoran","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nairong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congwen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Duo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0318-148X","authenticated-orcid":false,"given":"Yuwei","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2026.107398_bib0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nmd.2026.107398_bib0002","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","article-title":"Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis","volume":"93","author":"Damato","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2026.107398_bib0003","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.nmd.2026.107398_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1177249","article-title":"Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis","volume":"14","author":"Bi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2026.107398_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.553626","article-title":"Determinants of Quality of Life in Myasthenia Gravis Patients","volume":"11","author":"Szczudlik","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2026.107398_bib0006","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/mus.25397","article-title":"Early fast-acting treatment strategy against generalized myasthenia gravis","volume":"55","author":"Utsugisawa","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2026.107398_bib0007","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.107398_bib0008","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"issue":"Suppl 4","key":"10.1016\/j.nmd.2026.107398_bib0009","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1007\/s10072-003-0082-6","article-title":"Intravenous immunoglobulins in neurological disorders: safety issues","volume":"24","author":"Eibl","year":"2003","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nmd.2026.107398_bib0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14737175.2022.2057223","article-title":"Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.nmd.2026.107398_bib0011","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","article-title":"Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies","volume":"33","author":"Dalakas","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nmd.2026.107398_bib0012","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2026.107398_bib0013","article-title":"Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis","volume":"14","author":"Howard","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2026.107398_bib0014","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/acn3.52142","article-title":"Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China","volume":"11","author":"Luo","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2026.107398_bib0015","doi-asserted-by":"crossref","first-page":"8287","DOI":"10.1007\/s00210-025-03954-x","article-title":"A systematic review of efgartigimod as an effective treatment for myasthenic crisis","volume":"398","author":"Tang","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.nmd.2026.107398_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2026.107398_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2025.110457","article-title":"The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients","volume":"274","author":"Zhang","year":"2025","journal-title":"Clin Immunol"},{"key":"10.1016\/j.nmd.2026.107398_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00730","article-title":"Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study","author":"Guo","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nmd.2026.107398_bib0019","article-title":"Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2026.107398_bib0020","article-title":"Efficacy and safety of efgartigimod in the treatment of impending myasthenic crisis","volume":"17","author":"Li","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmd.2026.107398_bib0021","series-title":"Cancer clinical trials: methods and practice","first-page":"361","article-title":"The calculation and interpretation of survival curves","author":"Peto","year":"1984"},{"key":"10.1016\/j.nmd.2026.107398_bib0022","series-title":"Cancer clinical trials: methods and practice","first-page":"381","article-title":"Comparison of survival curves","author":"Breslow","year":"1984"},{"key":"10.1016\/j.nmd.2026.107398_bib0023","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2026.107398_bib0024","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nmd.2026.107398_bib0025","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nmd.2026.107398_bib0026","article-title":"Add-on efgartigimod in myasthenic crisis: a promising treatment option","volume":"16","author":"Shi","year":"2025","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2026.107398_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2024.578431","article-title":"Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series","volume":"395","author":"Hong","year":"2024","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2026.107398_bib0028","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00415-025-13367-8","article-title":"Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study","volume":"272","author":"Zhu","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2026.107398_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2026.e00837","article-title":"Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies","volume":"23","author":"Fuchs","year":"2026","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nmd.2026.107398_bib0030","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2026.107398_bib0031","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"K\u00f6hler","year":"2011","journal-title":"J Clin Apher"},{"key":"10.1016\/j.nmd.2026.107398_bib0032","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","article-title":"Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients","volume":"45","author":"Di Stefano","year":"2024","journal-title":"Neurol Sci"},{"key":"10.1016\/j.nmd.2026.107398_bib0033","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s40120-026-00923-1","article-title":"Efgartigimod in Patients with Generalized Myasthenia Gravis Refractory or Intolerant to IVIg","volume":"15","author":"D'Amico","year":"2026","journal-title":"Neurol Ther"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626010667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626010667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:00:56Z","timestamp":1791241256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896626010667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S0960896626010667"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2026.107398","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy of single-cycle intravenous efgartigimod versus intravenous immunoglobulin in generalized myasthenia gravis patients receiving concomitant immunosuppressive therapy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2026.107398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107398"}}